Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams

#2143

Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.

Aim(s): To evaluate the response of IBI308 in treating advanced NENs and to find out the effective population by using several biomarkers.

Materials and methods: We had prospectively enrolled patients pathologically diagnosed as NENs after standard treatment failure to receive IBI308 treatment. Most of patients had received IBI308 200mg q3w. Response was assessed every 9 weeks.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Xu J

Authors: Jia R, Li Y, Jin Y, Chen Y, Zhang Y,

Keywords: NEC, checkpoint blockade, anti-PD-1 antibody, NENs,